Advertisement
Product › Details
daratumumab
Next higher product group | antibody cancer drug | |
Status | 2015-09-04 registration pending | |
Organisation | Janssen Biotech Inc. (JBI) | |
Group | Johnson & Johnson (JnJ) (Group) | |
Organisation 2 | Genmab A/S (CSE: GEN, Nasdaq: GMAB) | |
Group | Genmab (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for daratumumab
- [1] MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg....
- [2] MorphoSys AG. (1/26/19). "Press Release: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab (Ad hoc)". Planegg....
- [3] Genmab A/S. (1/26/19). "Press Release: Genmab Announces that the Patents Asserted against Darzalex in the United States Have Been Declared Invalid by Summary Judgment". Copenhagen....
- [4] MorphoSys AG. (2/15/17). "Press Release: District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit with Janssen Biotech and Genmab". Planegg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top